These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1165 related articles for article (PubMed ID: 23537687)

  • 1. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
    van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
    Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
    Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
    Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis.
    Li MC; Wang ZY; Yang J; Guo XL; Wang T; Wang SG; Liu JH; Ye ZQ
    Asian J Androl; 2015; 17(1):124-34. PubMed ID: 25337836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
    Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
    BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
    Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
    Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin.
    Ko K; Yang DY; Lee WK; Kim SW; Moon du G; Moon KH; Park NC; Park JK; Son HC; Lee SW; Hyun JS; Park K
    Korean J Urol; 2014 Sep; 55(9):608-14. PubMed ID: 25237463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study.
    MacDiarmid SA; Peters KM; Chen A; Armstrong RB; Orman C; Aquilina JW; Nitti VW
    Mayo Clin Proc; 2008 Sep; 83(9):1002-10. PubMed ID: 18775200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.